新京报讯(记者张秀兰)12月22日,原发性胆汁性胆管炎(PBC)药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批,适用于与熊去氧胆酸(UDCA)联合治疗对UDCA单药应答不佳的PBC成人患者,或作为单药用于治疗无法耐受UDCA的PBC成人患者。该药也是全球首个获批用于治疗原发性胆汁性胆管炎的强效选择性过氧化物酶体增殖物激活受体δ(PPARδ)激动剂。 原发性胆汁性胆管炎是一种自身免疫性...
Source Link新京报讯(记者张秀兰)12月22日,原发性胆汁性胆管炎(PBC)药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批,适用于与熊去氧胆酸(UDCA)联合治疗对UDCA单药应答不佳的PBC成人患者,或作为单药用于治疗无法耐受UDCA的PBC成人患者。该药也是全球首个获批用于治疗原发性胆汁性胆管炎的强效选择性过氧化物酶体增殖物激活受体δ(PPARδ)激动剂。 原发性胆汁性胆管炎是一种自身免疫性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.